The FDA today approved icotrokinra (Icotyde; Johnson & Johnson) for the treatment of adults and pediatric patients aged 12 ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Add Yahoo as a preferred source to see more of our stories on Google. Having a dry, flaky scalp is one of the most frustrating scalp concerns to deal with. Whether from suffering from psoriasis on the ...
Morning Overview on MSN
FDA approves J&J’s once-daily Icotyde pill for plaque psoriasis
Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...
Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...
Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch ...
Tremfya is a biologic medication administered via injections into a vein or under the skin to treat plaque psoriasis. It works by blocking interleukin-23, a protein involved in the overactive immune ...
A standardized definition of on-treatment remission in plaque psoriasis is crucial for aligning treatment goals and improving patient care. Remission is defined as maintaining 0% BSA involvement or an ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results